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Abstract
Anthrax protective antigen (83 kDa, PA83) is an essential component of two major binary toxins 
produced by Bacillus anthracis, lethal toxin (LTx) and edema toxin (ETx). During infection, LTx 
and ETx contribute to immune collapse, endothelial dysfunction, hemorrhage and high mortality. 
Following protease cleavage on cell receptors or in circulation, the 20 kDa (PA20) N-terminus is 
released, activating the 63 kDa (PA63) form which binds lethal factor (LF) and edema factor (EF), 
facilitating their entry into their cellular targets. Several ELISA-based PA methods previously 
developed are primarily qualitative or semi-quantitative. Here, we combined protein 
immunocapture, tryptic digestion and isotope dilution liquid chromatography-mass spectrometry 
(LC-MS/MS), to develop a highly selective and sensitive method for detection and accurate 
quantification of total-PA (PA83 + PA63) and PA83. Two tryptic peptides in the 63 kDa region 
measure total-PA and three in the 20 kDa region measure PA83 alone. Detection limits range from 
1.3–2.9 ng mL−1 PA in 100 μL of plasma. Spiked recovery experiments with combinations of 
PA83, PA63, LF and EF in plasma showed that PA63 and PA83 were quantified accurately against 
the PA83 standard and that LF and EF did not interfere with accuracy. Applied to a study of 
inhalation anthrax in rhesus macaques, total-PA suggested triphasic kinetics, similar to that 
previously observed for LF and EF. This study is the first to report circulating PA83 in inhalation 
anthrax, typically at less than 4% of the levels of PA63, providing the first evidence that activated 
PA63 is the primary form of PA throughout infection.
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Introduction
Bacillus anthracis, the causative agent of anthrax in humans and animals, is a Gram-positive 
spore-forming pathogen that is widely distributed in the environment.1 Naturally occurring 
human anthrax manifests as cutaneous, gastrointestinal and inhalation forms, with cutaneous 
being the most common accounting for 95–98% of reported cases with a 20% mortality if 
untreated or <2% with antibiotic treatment.1–3 Inhalation anthrax is the most deadly form, 
with a fatality rate of approximately 90% without treatment.2 Recently, a new form of 
anthrax resulting from intravenous drug use was recognized, which was linked to heroin 
contaminated with B. anthracis spores.4 The main virulence factors include three proteins, 
protective antigen (PA, a binding and translocation protein), lethal factor (LF, a zinc-
dependent endoproteinase) and edema factor (EF, an adenylate cyclase). These proteins 
combine to form two toxins, lethal toxin (LTx; formed from PA and LF) and edema toxin 
(ETx; composed of PA and EF) that have synergistic effects in suppression of the host 
immune response.5
The mechanisms of action for PA, LF and EF have been studied extensively.5,6 B. anthracis 
spores are phagocytized by macrophages where they germinate. The resulting vegetative 
cells express full-length PA (PA83; 83 kDa), LF (90 kDa) and EF (89 kDa). The individual 
proteins are relatively harmless on their own and PA83 does not appreciably bind either LF 
or EF.7 It is well established8 that domain 4 of PA83 binds to two known receptors on the 
host cell surface, tumor endothelium marker 88,9 and capillary morphogenesis protein 2.10 
There it is cleaved by furin-like protease activity11 to a 63 kDa form (PA63) with loss of the 
20 kDa N-terminal region (PA20). Recently, it has been reported that PA83 has calcium-
dependent protease activity.12 The PA63 self-associates into a heptamer6 or an octamer,13 
which can then bind 3 or 4 molecules of LF and/or EF, thus forming LTx, ETx and possibly 
mixed toxin complexes. The PA63 oligomers form pores on the endosome membranes 
through which LF and EF are transported into the cytosol, where their combined enzyme 
activities exert potent synergistic toxic effects.14
It has been demonstrated that PA83 is not only cleaved and activated at cell surfaces, but is 
also cleaved to PA63 by the action of serum proteases and that functional LTx is found in 
blood in late stage infection.7,14,15 The serum cleaved form is found bound to LF as LTx and 
circulating in serum throughout infection.16 However, to date, no free PA83 has been 
detected in blood, although the PA20 fragment has been found.17 The ratio of PA83 to PA63 
throughout infection has not been described.
Diagnosis of inhalation anthrax can be challenging because initial symptoms are 
nondescript, yet the disease can rapidly progress without treatment.1,18 Methods available 
for confirmation of anthrax infection include a wide range of antibody-based, nucleic acid-
based, and phenotypic approaches19,20 that encompass diverse targets including spore and 
vegetative cell markers, PA, LF, EF and their complexes, gamma-linked poly-D-glutamic 
acid (PGA) capsule, and bacterial mRNA and DNA. As part of the efforts to improve 
diagnosis of anthrax, a sensitive and specific mass spectrometry (MS) method for detection 
of LF in serum and plasma was developed and fully validated.21,22 The LF MS method was 
recently included as a confirmatory anthrax diagnostic method in the updated Council of 
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State and Territorial Epidemiologists (CSTE) clinical case classification for human anthrax.
23
 Its use in experimental anthrax revealed a triphasic progression of inhalation anthrax in 
rhesus macaques characterized by a rise-plateau-rise of LF over time.24 The two phases of 
rapid toxin increases are typically separated by a period of variable length in which toxins 
plateau or decline (phase-2). This fits the clinical staging of inhalation anthrax described 
with a first, early prodromal phase, a second, intermediate/progressive stage, and a third, 
late-fulminant stage, with a low survival probability.25 EF has recently been shown to have 
similar triphasic toxin kinetics but is typically present at much lower levels during anthrax 
infection compared to LF.26 The levels and kinetics of PA at all stages of anthrax have not 
yet been reported and an understanding of these may tell us more about the course of disease 
and potential outcomes with inhalation anthrax. The importance of obtaining an overall 
picture of anthrax toxins has been stressed by others.27,28
A range of qualitative and quantitative immunocapture-based methods for PA developed for 
various clinical and research purposes were reviewed in 2006.20 Some more recent 
immunoassay PA methods have used traditional ELISA,29,30 electrochemiluminescence 
(ECL)30,31 and time-resolved fluorescence (TRF).32,33 Some alternative approaches have 
included fluorescence methods.18,34 Taken overall, and given different approaches for 
determination of the limits of detection (LOD), the LODs appeared to range from 0.0001 to 
83 ng mL−1 PA for these methods. However, many of the more sensitive measurements have 
not been achieved on relevant clinical samples such as plasma or serum. In general, lower 
method LOD’s would provide the opportunity for earlier detection of anthrax infections 
(during phase-1 or phase-2), and therefore facilitate more successful treatment outcomes. 
Currently, an MS-based method for LF appears to provide the earliest time to detection, with 
LF levels in a non-human primate model ranging from 0.015–1.39 ng mL−1 from 18–24 
hours after high spore dose exposures.22 By 48 hours, the average time of symptom onset, 
LF levels ranged from 4.87–468 ng mL−1. PA levels in New Zealand White rabbits 
measured by ECL ranged from approximately 2–200 ng mL−1 at 48 hours after high dose 
exposures.35 In the context of an intentional release, index cases will typically present with 
symptoms and toxin levels above detection limits of most methods (i.e. around 1 ng mL−1). 
Methods with lower detection limits, such as the MS-based LF method,22 may be useful for 
diagnosing pre-symptom onset exposures from a known release.
A traditional sandwich ELISA was developed with specific antibodies capable of 
distinguishing PA63 and PA83 to study cleavage and clearance of PA from blood.15 A highly 
sensitive immunoassay using europium nanoparticles for detection has been reported.32 The 
LOD was found to be about 0.02 ng mL−1 for PA in plasma, but it was only found to be 
suitable for qualitative or semiquantitative analysis. A PA ELISA using a europium anti-PA 
IgG for TRF was applied to inhalation anthrax samples.33 Though not differentiating the two 
PA forms, it tested recovery of both PA83 and PA63 and achieved reliable detection limits of 
0.551 and 1.58 ng mL−1, respectively. However, the precision and accuracy achieved 
suggested the method was more appropriate for qualitative analysis of clinical samples. 
Other ECL methods have been utilized for PA83 quantitation in New Zealand white rabbits.
35
 The authors described acceptable but limited assessment of accuracy and precision with a 
lower limit of quantitation of 0.5 ng mL−1 PA83 in plasma. However, the full method 
quantitative parameters and validation were not described and the method did not assess 
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recoveries of PA63.35 Qualitative ECL and quantitative ELISA methods have been used to 
study inhalation anthrax in cynomolgus macaques.36 Although an LOD of 2.4 ng mL−1 PA 
in serum using ELISA was reported, the form of PA was not defined and very limited details 
of the quantification are given.36 To date, no methods have been applied to quantify and 
investigate the presence of both full length PA83 and active PA63 forms throughout the 
course of experimental inhalation anthrax.
Isotope dilution LC-MS/MS (IDMS) is ideally suited for accurate and sensitive quantitative 
methods and can provide a level of specificity that is generally not possible with 
fluorescence or luminescence tagged antibody detection systems. The MS methods 
developed in our laboratory for LF and EF employ antibody capture, enzymatic activity and 
IDMS strategies.16,21,22,24,26,37 Here, we describe an antibody capture, on-bead tryptic 
digest, and IDMS method for the quantification of anthrax PA. This represents the first use 
of magnetic antibody bead capture for PA, combined with on-bead tryptic digestion, 
releasing PA peptides for LC-MS/MS quantification of targeted regions of PA. A 
combination of two antibodies were able to capture and purify both full length PA83 and 
active PA63, as they both bind to the PA63 region and not to the N-terminal PA20 region. 
Therefore, quantification of peptides within the 20 kDa region gave a measure of full length 
PA83 and peptides within the 63 kDa region gave a measure of both PA83 and PA63 (total-
PA). The difference between the two provides a measure of active PA63 competent for 
cellular intoxication. We validated the method and applied it to differentiate and quantify the 
forms of PA in serum of five rhesus macaques (Macaca mulatta) with inhalation anthrax. 
These measurements were compared to previously published PA, LF, PCR and bacteremia 
results.24
Experimental procedures
Materials
Recombinant anthrax toxins PA83, PA63, LF and EF were from List Biological Laboratories 
(Campbell, CA). Normal North American (NNA) human ten-donor-pooled serum and 
plasma, and plasma (with EDTA anticoagulant) from 100 individual NNA donors were 
obtained from Interstate Blood Bank (Memphis, TN), Anti-PA mouse monoclonal antibodies 
(mAb) AVR1046 and AVR1162 were prepared at CDC by the Division of Scientific 
Resources,21 Invitrogen™ DYNAL™ Dynabeads™ MyOne™ tosyl-activated magnetic 
beads (MB) were from ThermoFisher Scientific (Waltham, MA), 1× phosphate buffered 
saline with 0.05% Tween-20 (PBST) was from Growcells (Irvine, CA), 0.1% Formic Acid 
(FA) in water and 0.1% FA in Acetonitrile (ACN) were from ThermoFisher Scientific, 
RapiGest™ SF Surfactant (Waters Corporation, Milford, MA), Sequencing grade modified 
trypsin was from Promega, (Madison, WI). PA peptide 13C, 15N isotopically labeled 
internal standards (IS) included (I + 7)QYQR (for tryptic peptide T12), G(L + 7)DFK (for 
T14), EVISSDN(L + 7)QL (P + 6)ELK (T17), D(L + 7)NLVER (T54), and NN(I + 7) 
AVGADESVVK (T67) were custom made by MidWest Bio-Tech, Inc. (Fishers, IN). 
Unlabeled native forms of the same peptides were synthesized and quantified by amino acid 
analysis by New England Peptide (Gardner, MA). All chemicals were of the highest purity 
available and used without further purification.
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Animal study protocol
Sample aliquots remaining from a previous approved protocol were used for this method.24 
Briefly, five female rhesus macaques obtained from Covance (Alice, TX) were anesthetized 
and challenged via head-only with B. anthracis Ames spores at a calculated aerosol dose of 
GMC ± SE of 378 LD50 ± 8% equivalents, higher than the target spore dose of 200 LD50 
with exposure times ranging from 10 to 30 minutes.24 Though the spore dose delivered was 
higher than the target, it corresponds to that used in previously reported studies designed to 
yield high infection rates.38
Animals were challenged at the Battelle Biomedical Research Center (Columbus, OH) and 
the study protocol was approved by Battelle (protocol no. 570, carried out 2006–2007) and 
the Centers for Disease Control and Prevention’s (CDC) Institutional Care and Use 
Committees (IACUC; protocol no. 1459BOYMON) following National Institutes of Health 
(NIH) guidelines for the care and use of laboratory animals. Serum from the 5 macaques 
reported here was collected at 42 days pre-exposure and at 2, 4, 6, 12, 24, 48, 72, 96 and 120 
hours post-exposure for the analysis of LF, PA and PGA. For the present study, only those 
samples with sufficient volume remaining were analyzed for PA.
Characterization of PA and peptide selection
Recombinant PA83 was the primary standard material used for quantification in this method. 
Relative amounts of PA63 and PA83 in different purchased lots of material over several 
years were confirmed to be within 20% of each other using the ‘High-3’ relative protein 
quantification method39 on tryptic digests by nanoflow LC-MS/MSE on a Synapt G2S 
(Waters Corporation) high resolution accurate mass system. Unambiguous tryptic peptide 
and MS/MS fragment identifications40 were obtained by comparison with the expressed PA 
sequence in UniProtKB P13423. These findings formed the basis for selection of the 5-
tryptic peptides used in this work, along with optimal internal standard isotopic label 
positions and multiple reaction monitoring (MRM) transitions, Table 1. Three peptides fall 
in the N-terminal 20 kDa region and two in the 63 kDa region.
Antibody capture optimization
The two anti-PA mAbs both capture PA83 and PA63 (total-PA). The AVR1046 epitope is 
within domain 4 (PA residues 625–764; P13423).33,41 AVR1162 binds both PA83 and 
PA63.33 Recoveries of PA83 and PA63 at 5 and 25 pmol mL−1 were evaluated, using 
AVR1046 and AVR1162 both individually and combined.
Recombinant PA83 standard purity assessment
It was necessary to verify the purity and quantify the amount of PA83 in the recombinant 
material used in the method. Therefore, the recombinant PA83 was independently quantified 
by isotope dilution LC-MS/MS using peptide-based calibration curves. Briefly, five-point 
peptide standard calibration curves for the 5 native peptides were prepared based on 
concentrations obtained by amino acid analyses. Aliquots of recombinant PA83 in 50 mM 
ammonium bicarbonate were subjected to tryptic digestion following a procedure similar to 
that described below but without the antibody capture. Internal standard peptides were added 
and calibration curves over the range 60–300 pmol mL−1 final concentration were fitted by 
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linear regression. Results of this peptide-based quantification of the PA83 material 
confirmed that the amounts were correct, within the experimental error of the method.
Sample preparation
Appropriate safety control measures, including engineering, administrative, and personal 
protective equipment, were used for all procedures based on a site-specific risk assessment 
that identified physical, health and procedural hazards.
Recombinant PA83 was spiked into plasma pools to produce a calibration curve with 10 
standards concentrations spanning between 0.017 to 333 pmol mL−1 along with quality 
control (QC) pools at 2.75 (QCL) and 60 (QCH) pmol mL−1. A plasma blank was also 
included. Standards and QC pools were aliquoted and kept frozen at −70 °C until further 
use. Anti-PA mouse monoclonal antibodies (mAb) AVR1046 and AVR1162 were prepared 
as described previously,33 and then individually cross-linked to magnetic antibody beads 
following manufacturer’s instructions. The resulting antibody coated beads solutions were 
mixed 1 : 1 (v/v) to allow for optimal dual antibody binding to the tosyl-activated MBs.
Three steps are followed for PA analysis. In step 1, PA is bound to dual anti-PA magnetic 
beads (PA-MB). Except for plate preparation, all events were carried out using a KingFisher 
Flex purification system 96 plate (ThermoFisher Scientific, Waltham, MA). Blanks, 
standards, QCs and unknown samples were spiked at 100 μL of each, with 900 μL of PBST 
buffer in a deep 96-well plate. 20 μL PA-MB per sample were resuspended in 70 μL of 
PBST buffer in a separate 200 μL 96-well plate. PA-MB were mixed with the samples, for 1 
hour PA binding, then transferred and washed twice in 1 mL PBST for 1.5 minutes each, 
then two times in 200 μL dH20 for 1.5 minutes after which, the beads were released and 
collected. The beads were manually transferred with multi-channel pipette from the final 
plate to a 24 or 48-well PCR plate from Molecular Products, Inc. (San Diego, CA) on a 
DynaMag™ 96 side magnet plate (ThermoFisher Scientific) and dH20 was removed from 
the PA-MB’s.
In Step 2, PA is hydrolyzed by trypsin with an on-bead tryptic digest. All events were carried 
out in a GeneAmp® PCR system 9700 thermal cycler (ThermoFisher Scientific). In general, 
plates were capped and mixed at 1500 rpm for 2 minutes using an Eppendorf MixMate 
mixer (Eppendorf, Hauppauge, NY) after the addition and/or incubation steps. Briefly, after 
water removal, 10 μL of 0.2% RapiGest in 50 mM ammonium bicarbonate was added to 
each sample, heated for 10 minutes at 99 °C, then cooled to 4 °C. Then 10 μL with 1.3 μg of 
sequencing grade modified trypsin (pre-diluted 1 part trypsin to 2 parts 50 mM ammonium 
bicarbonate) was added, samples incubated at 42 °C for 2 hours, then cooled at 4 °C. Lastly, 
a PA internal standard (IS) solution was prepared prior to addition by adding 200 μL of the 
PA IS mix containing the PA isotopically labeled peptides to 400 μL of 0.45 M HCL. 10 μL 
of this PA IS solution was added, then samples were incubated for 1 hour at 37 °C, then 
cooled at 4 °C. The sample plate was mixed, then centrifuged for 30 minutes at 4 °C at 2204 
rcf, placed on the magnet and 25 μL of the digested sample mixture was placed in individual 
LC vials for LC-MS/MS analysis.
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Step 3 includes isotope-dilution LC-MS/MS for analysis of specific tryptic peptides over the 
length of PA, including three in the 20 kDa and two in the 63 kDa regions. Details of LC-
MS/MS are described below.
LC system
A Waters Acquity UPLC® system (Waters Corporation) was used for all LC-MS/MS 
analyses. An Acquity UPLC® BEH reverse phase C18 1.0 × 100 mm ID, 1.7 μm particle 
size analytical column (Waters) was used for all separations. The column was kept at 50 °C 
and the autosampler at 6 °C throughout all analyses, and the sample injection volume was 10 
μL. The aqueous mobile phase (A) and the organic mobile phase (B) consisted of 0.1% FA 
in water and 0.1% FA in acetonitrile respectively. Peptides were separated using a linear 
gradient from 2.5% (v/v) B to 35% (v/v) B in 13 minutes at 200 μL min−1, and the cycle 
time was 16.5 minutes including a high-organic wash and reequilibration to initial 
conditions.
Mass spectrometer
A QTRAP® 6500 triple quadrupole mass spectrometer (AB Sciex LLC, Framingham, MA) 
with an IonDrive Turbo-V ion source operating in standard positive ion electrospray 
ionization (ESI) mode and multiple reaction monitoring (MRM) at unit resolution was used 
for all LC-MS/MS analyses. PA tryptic peptide data were acquired using MRM transitions 
as listed in Table 1 for 5 native and 5 corresponding isotopically labeled PA tryptic peptides. 
The isotopic labels confer identical chemical properties, such as retention time, whilst 
making these internal standard peptides fully distinguishable based on their mass differences 
(7 or 13 Da, depending on the peptide) compared to the native forms. In each case, the m/z 
values were chosen based on theoretical models of the peak tops of the isotopic envelopes at 
80% height at the 0.7 full width half-maximum quadrupole resolution used. Two MRM 
transitions were included for each tryptic peptide, with expected signal ratios being used to 
confirm correct peak identifications. Fixed instrument parameters included curtain gas 35, 
collision gas High, ion spray voltage 5500 V, source temperature 350 °C, ion source gas 1 
(GS1) 50, and ion source gas 2 (GS2) 50. Declustering potential (DP) and collision energy 
(CE) voltages were optimized for each individual peptide. Instrument control and data 
acquisition were performed using Analyst software v1.6.2.
Data processing and quantification of PA
Analyst Quantification Results tables were built for each analytical run, and then raw 
chromatograms and sample information (but not peak areas) were exported using custom 
VB. Net automation programs. All peak integration, quantitation and reporting functions 
were fully automated by a custom VB. Net program, with minimal manual intervention. 
Performance of the custom software for quantification purposes was confirmed to be 
identical to that of Analyst v1.6.2 (data not shown), whilst providing a wider range of 
capabilities and improved ease of use. The custom software included functions for least-
squares fitting of calibration curves based on equally-weighted log10 peak area ratios 
(native/internal standard areas) and log10 given amounts using 3rd-order (cubic) polynomials 
as required for the PA method, and for reporting quantitative measurements at the peptide 
and protein levels after combining results for groups of MRM transitions.
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Limits of detection (LOD) were calculated for individual MRM pairs (for the native and 
corresponding internal standards) using statistical methods similar to those described 
previously16 based on the first 22 analytical runs. LOD’s were in the region of 0.018 to 
0.035 pmol mL−1 for the most sensitive MRM transition from each peptide (equivalent to 
1.3 to 2.9 ng mL−1 for the PA83 mass), Table 1. Total-PA (PA63 + PA83), was quantified by 
averaging signals above the LOD’s from peptides T54 and T67 (Fig. 1). Similarly, full 
length PA83 was quantified by averaged signals from peptides T12, T14 and T17 (Fig. 1). 
To ensure quality, signals from a minimum of two MRM transitions and two peptides were 
necessary for a positive result in all cases. To be included in the quantitative measurements, 
each MRM signal was also required to be within the range of the standard curve, and to have 
a peak area ratio that was 3-fold or more above that of the plasma blank sample in the same 
analytical run. The application of these filters along with multiple MRM transitions and 
multiple peptides conferred both robustness and specificity on the quantitative 
measurements. These calculations were carried out in units of pmol mL−1, after which the 
reported amounts of total-PA, PA83 and PA63 (obtained by subtracting PA83 from total-PA) 
could be converted to ng mL−1.
Method validation
Data from 22 analytical runs acquired over a 10-week period by one analyst using one LC-
MS/MS instrument were collected. Quantitative measurements were obtained for total-PA 
and PA83 alone as described above for the two QC materials at 2.75 pmol mL−1 and 60 
pmol mL−1. The 2.75 pmol mL−1 QC pool yielded combined MRM means and coefficients 
of variation (%CV’s) of 2.69 (5.3%) and 2.70 pmol mL−1 (5.3%) for total-PA and PA83 
respectively, both with errors of 1.0%. The means and CVs for the 60 pmol mL−1 QC pool 
were 59.0 (5.7%) and 59.0 pmol mL−1 (6.3%) for total-PA and PA83 respectively, both with 
errors of 1.7%. Quality control procedures met the requirements for quantitative analytical 
LC-MS/MS methods.42
Results and discussion
Method development and performance
The binary anthrax toxins affect the outcome of infection in various ways, exerting 
deleterious effects on different tissues.43 LF, LTx and EF levels have been quantified16,22,26 
but less is known about PA levels and its forms during the course of infection. This 
knowledge is needed to understand the progression of anthrax and which PA forms are the 
most appropriate targets for therapeutic interventions. The PA mass spectrometry method 
described here complements the LF and EF methods in use in our laboratory for the 
comprehensive study of anthrax toxin levels during infection and treatment. The organism 
secretes full-length PA83 monomer, which is known to be processed to the active PA63 
form. Therefore, both forms are anticipated to be found in vivo. The method is different 
from most others developed for PA,15,32,33 in that it is the first to (1) combine quantification 
of both PA83 and PA63, (2) employ targeted MS-based peptide specificity, (3) include full 
validation and (4) be applied to measure both forms throughout the all stages of inhalation 
anthrax in a non-human primate model.
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The overall strategy for analyzing both PA forms was to extract total PA by targeting the 
carboxy-terminal domains for magnetic antibody bead capture purifying both PA83 and 
PA63 (total-PA) (Fig. 1). Tryptic digest on the beads would release peptides over the length 
of all PA forms extracted. PA20 peptides would only be present in full length PA83 (PA83), 
whereas PA63 peptides would be present in both PA83 and PA63 (total-PA). As measured by 
LC-MS/MS, the difference between total-PA and PA83 would give the amount of PA that is 
active PA63. Following PA-targeted mAb capture, tryptic digestion yields the peptide targets 
indicated (Table 1 and Fig. 1). The peptides identified were unique and two, T54 and T67, 
present in both PA forms, quantify total-PA, whereas T12, T14, and T17, present only in 
PA83, quantify PA83.
Typical LC-MS/MS performance for a high-level PA83 plasma standards sample is shown in 
Fig. 2, with chromatograms of the 5 native PA peptides and their associated internal standard 
peptides. Signal over the range of calibration standards from 0.017 to 333 pmol mL−1 were 
best modeled for all peptides with equally weighted log10 peak area ratios (native/internal 
standard areas) and log10 given amounts using 3rd-order (cubic) polynomial fits (Fig. 3). In 
addition to the 22 analytical runs used for method validation, a further 49 analytical runs 
have been obtained to date (most of which were for additional inhalation anthrax studies not 
described here). The 71 analytical runs gave precision <7.0% CV for the QC materials, 
providing confidence of the general suitability and robustness of this method.
Antibodies were selected with the strategy to target domains 2–4 and pull out both full 
length PA83 and active PA63. AVR1046 was selected since the epitope was previously 
mapped to domain 4 (PA residues 625–764; P13423).33,41 AVR1162 was also selected 
which was shown to bind both PA83 and PA63 but not compete with AVR1046.33 
Assessment of recoveries for AVR1046 and AVR1162 both alone and combined (2 mAbs) 
showed that 2 mAbs improved recovery of PA83 up to 16% (to a total of 89%) over that of 
AVR1046 alone at 5 and 25 pmol mL−1 PA83 protein concentrations in plasma. However, 
recovery of PA63 with AVR1046 alone was high (87%) and no further enhancement was 
gained by addition of AVR1162. Overall, AVR1046 was sufficient for recovery of PA63, and 
AVR1162 improved recovery of PA83 indicating that the combination of the two anti-PA 
mAbs was beneficial for total-PA recoveries. The use of full-length PA83 as the standard for 
quantification has the advantage that all samples (standards, QCs, blanks and unknowns) are 
subject to the same antibody extraction procedure and all following steps (digestion, LC-
MS/MS). The use of standards and QC’s on the same plate therefore largely corrects for the 
recovery of the antibody extraction and the digestion. Accuracy of the LC-MS/MS analysis 
is based in the use of isotope labeled peptide internal standards.
Recombinant PA83 used as a primary standard material in our method was quantified using 
five amino acid-based synthetic peptide standard curves (Table 1). A mean recovery of 
95.3% of the expected level of recombinant PA83 with standard deviation of 13.2% (N = 20) 
was obtained. This confirmed that the assigned level of PA83 was correct within an 
acceptable experimental error for this type of measurement.
The reports that PA83 is activated to PA63 by serum proteases in vivo7,14 are relevant as to 
whether the recombinant PA83 spiked in EDTA-plasma in our primary standards would also 
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be cleaved to PA63. This could hinder accurate quantification of the peptides in the PA20 
region (T12, T14 & T17). Confirmation of stability in plasma was obtained by comparisons 
of peptide signals from the PA83 in the plasma standards (stored at −70 °C for 3 years) with 
peptide signals from the same batch of recombinant PA83 prepared in buffer alone. The 
plasma standards were subjected to antibody capture and tryptic digest, but the PA83 in 
buffer only required tryptic digestion for this purpose. The ratios of absolute signals for the 
target peptides representing the total-PA and PA83 measurements differed by 5% (within 
experimental error), indicating minimal conversion of PA83 to PA63 in our spiked primary 
plasma standards.
The spiked plasma QC materials were further assessed for stability using conditions that 
might occur during sample handling procedures (ESI, Tables S1–S3†). The results for total-
PA and PA83 were all within the FDA-recommended 15% of the established QC values for 
each QC material.44
Interferences in the context of complex infection samples were also assessed. Plasma spiked 
with combinations of recombinant PA63, PA83, LF and EF was evaluated for anthrax toxin 
recovery and accuracy, Table 2. A total of 24 individual samples were prepared, which were 
then analyzed in 3 or 4 analytical runs performed on different days to provide technical 
replicates. Three levels of PA63 and PA83 were chosen spanning the working range of the 
PA method, along with levels of LF and EF chosen to model possible ratios in inhalation 
anthrax samples. Accuracy and precision of the total-PA, PA63 and PA83 measurements 
were acceptable alone and in all combinations with other toxin components. In samples 
spiked with both PA63 and PA83, total-PA measurements were doubled as expected. These 
results confirm that the combined Ab capture and trypsin hydrolysis are equally effective for 
PA63 and PA83, and that the presence of either LF or EF has no adverse effect on the 
performance of the method.
Our strategies for combining multiple peptide MRM results per PA region improves 
assurance of the correct result and reporting high-quality protein-level measurements. This 
also improves selectivity with the requirement for two or more peptide results. Selectivity 
was evaluated by analyses of known blank samples (10 human plasma, 10 human serum), 
and 5 pre-exposure rhesus macaque plasma samples. All yielded negative results for all 5 
peptides and MRM’s. The ng mL−1 equivalent LODs of 1.3 to 2.9 ng mL−1 obtained during 
validation were confirmed in practice with the comprehensive analysis of 1350 positive and 
negative anthrax infection samples, for which overall detection limits for both total-PA and 
PA83 were found to be in the region of 2.2 ng mL−1 (data not shown). While these detection 
limits are not better than some reported previously, this is the first method to do so with 
good accuracy and precision over a range of concentrations and conditions relevant to those 
seen during inhalation anthrax (Table 2).33
Inhalation anthrax toxin levels in a rhesus macaque model
Serum samples from five rhesus macaques exposed to high doses of B. anthracis Ames 
strain spores by inhalation were previously analyzed by PA ELISA, LF, pagA (the protective 
†Electronic supplementary information (ESI) available. See DOI: 10.1039/c8an02479k
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antigen gene) PCR and blood culture (bacteremia).24 Subsequently, the same samples were 
analyzed for PA using this new immunocapture, trypsin digest and IDMS method. Table 3 
and Fig. 4 show selected results from the original study along with total-PA, PA83 and PA63 
measurements using the new MS method. The PA MS measurements update and replace the 
earlier PA ELISA measurements (retained in Fig. 4 for comparison). Table 3 also includes 
two updated values for LF, using an improved dual-antibody method developed in our 
laboratory.22
All pre-exposure samples (collected at −42 days) were negative for all methods, total-PA, 
LF, PCR and culture (data not shown). Analysis of the samples using MS showed that total-
PA was first detected in all 5 animals at 48 hours, when culture and pagA PCR were first 
positive (Table 3). Total-PA was consistently detected and quantified at all subsequent time 
points. As with LF, total-PA was consistently positive at 72 hours when cultures were 
negative in some animals. PA83 was only detected in four samples, of which three were at 
death/euthanasia. In these four samples, ratios of PA83 compared to total-PA were low, from 
0.6 to 3.9%. The theoretical w/w ratio of PA63 : LF in complex is 1.4 (PA63 octamer/4 LF)6 
or 1.6 (PA63 heptamer/3 LF).13 We showed previously that the amount of LF complexed 
with PA63 (LTx) ranged from 5% in early infection up to 100% in late stages.16 The 
observed ratios of PA to LF here range from 1.6–15.8 with a mean of 6.6. This suggests that 
there is excess active PA63 circulating providing a reservoir for continued toxin formation. 
The results clearly show that PA63 is the primary form of PA present in serum throughout 
infection.
PA63 levels appeared to be consistent with the triphasic progression reported for LF24 and 
EF26 previously. In the presented study on rhesus macaques, the detection limits and 
granularity of sample collection did not show the full triphasic profiles, however we have 
observed this pattern in PA63 in other animal inhalation anthrax studies not reported here. 
PA63 was not detected at 24 hours for animals A, C, and D. That is because the lowest LF 
levels reported in animals A, C and D at 24 hours (Fig. 4) were in the 0.006–0.200 ng mL−1 
range, suggesting that PA levels were below the PA MS method LOD. But by 48 hours the 
LF levels increased more than 100-fold at the end of phase-1 into easily detectable ranges 
for PA MS. At phase-1 (48 hours), PA63 ranged from 84.3–310 ng mL−1, then at phase-2 
(72 hours) declined or plateaued to 74–163 ng mL−1, then at phase-3 (96–120 hours, except 
for animal D), increased to 236–42 435 ng mL−1 (Table 3). PA results found for animal D 
were the lowest among all animals and the kinetic profiles were similar to LF with phase-2 
declines lasting two days (from 48–96 hours) before starting to rise at 120 hours.24 This 
animal did not reach terminal stage until 9 days after exposure but samples later than 5 days 
were not available because of the study design and IAUAC protocol.
This work supports previous studies that found PA63 in late stages of infection in various 
animal models.7,15 It is important to highlight that the detection of PA83 observed in the 
serum of animals A, B and E represents the first report of this form during inhalation 
infection. As discussed, detection of full-length PA83 was based on the measured target 
peptides T12, T14 and T17 in the PA20 region of the protein. PA83 was measured in only 
one animal at an early time point, at 4.4 ng mL−1 at 48 hours (animal A). This animal had 
the highest total-PA levels, 314 ng mL−1, at that early time point. PA83 was also positive at 
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terminal time points in animals A, B, and E, in samples that also had the highest total-PA 
levels. That PA83 is only found transiently and at low ratios compared to PA63 and in these 
animals only when PA was higher, suggests that its hydrolysis is ongoing and that PA83 is 
detectable when organism and toxin burdens exceed certain levels. The processes of ongoing 
cellular toxin binding and uptake, intoxication and receptor turnover, along with the ongoing 
progression of infection, bacteremia and continued release of PA83, LF and EF, complicate 
the dynamics.
Conclusions
In this study, a precise, accurate and highly selective method quantifying total-PA and PA83 
was developed, validated and applied. We showed that PA63 and full-length PA83 were both 
present and successfully quantified in vivo in sera of rhesus macaques with inhalation 
anthrax. The significance of the amounts of PA63 and PA83 found during anthrax infection 
warrants further analysis. The work presented here was developed to provide a better 
understanding of anthrax toxemia and to elucidate the degree of PA processing during the 
different stages of anthrax infection. These findings complement the existing LF, LTx, EF 
and ETx measurements by mass spectrometry in our laboratory in these samples and can 
potentially improve our understanding of anthrax.
In comparison to traditional and previously reported methods for the detection of anthrax 
PA, mass spectrometry in combination with antibody immunocapture and tryptic digestion 
provides the necessary analytical selectivity for the accurate identification and quantification 
of different PA species in serum or plasma.
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Fig. 1. 
Quantification strategy using select PA tryptic peptides. Epitopes for both anti-PA mAbs are 
within PA domains 1b through 4, such that both full-length PA83 and truncated PA63 are 
captured. Free PA20 (not shown) is not captured. Proteotypic peptides are indicated by 
orange stars. Signals from peptides T54 and T67 are representative of total-PA (PA63 + 
PA83), and signals from peptides T12, T14 and T17 are representative of PA83.
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Fig. 2. 
Typical chromatographic performance of the anthrax protective antigen method, for a high 
standard (12.34 pmol mL−1 PA83). (A) Individual signals from 10 analyte MRM transitions 
for the 5 native target peptides T12–T67, and (B) corresponding signals from the 10 internal 
standard MRM transitions (Table 1) for isotope dilution quantification. In this PA83 standard 
sample, the levels of peptides in the internal standard mixture gave approximately the same 
signal intensities as the native peptides. These internal standard levels gave optimal 
quantitative performance using area ratios, without any observed LC column carryover or 
isotopic interferences.
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Fig. 3. 
Normalized analyte/internal standard peak area ratios from the set of 10 standards in one 
analytical run, for 5 out of the 10 MRM pairs listed in Table 1. The standards points for each 
MRM are joined by straight lines to highlight the slight curvature, in support of 3rd-order 
polynomial curve fitting (not shown). The standards concentrations range between 0.017 and 
333 pmol mL−1 of PA83 in human plasma.
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Fig. 4. 
Progression of inhalation anthrax in rhesus macaques. PA63 and PA83 profiles for inhalation 
anthrax in 5 macaques (A–E) obtained by immunocapture, tryptic digest and IDMS are 
shown in black and green respectively. PA results are plotted here on a log10 scale and are 
compared to LF values (in blue) and PA ELISA (orange) previously reported by Boyer et al.
24
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